Skip to main content
Premium Trial:

Request an Annual Quote

Friz Biochem Raises 3M to Develop DNA Microarray Platform Further

NEW YORK, March 28 - Friz Biochem of Munich has raised €3 million in the first closing of a Series B financing round, the company said today.


Existing shareholder Global Life Science Ventures led the round, joined by DRF Beteiligungsgesellschaft as a co-investor.


The company expects to raise additional funds, including soft loans, in a second closing.


Friz develops a DNA microarray platform with an electrical readout technology. It plans to use the funding to establish pilot production capabilities and to validate the arrays in the areas of food pathogens and clinical diagnosis.


For further information, see the company statement.

The Scan

Boosters Chasing Variants

The New York Times reports that an FDA advisory panel is to weigh updated booster vaccines for COVID-19.

Not Yet

The World Health Organization says monkeypox is not yet a global emergency, the Washington Post reports.

More Proposed for Federal Research

Science reports that US House of Representatives panels are seeking to increase federal research funding.

PLOS Papers on Breast Cancer Metastasis, Left-Sided Cardiac Defects, SARS-CoV-2 Monitoring

In PLOS this week: link between breast cancer metastasis and CLIC4, sequencing analysis of left-sided cardiac defects, and more.